First European Cancer Injection
- LONDON (AP) — Starting next June, the United Kingdom's National Health Service (NHS) will introduce subcutaneous injections of Nivolumab (Opdivo) for the treatment of 15 types of cancer,...
- Nivolumab is an immunotherapy drug that works by blocking a protein that inhibits the immune system, thereby enabling it to attack cancer cells.
- Previously, Nivolumab was administered intravenously over a period of 30 to 60 minutes.
UK’s NHS to Offer Faster Cancer Treatment wiht Subcutaneous Nivolumab
LONDON (AP) — Starting next June, the United Kingdom’s National Health Service (NHS) will introduce subcutaneous injections of Nivolumab (Opdivo) for the treatment of 15 types of cancer, making the UK the first European nation to utilize this method, according to the vietnam News Agency (VNA).
Nivolumab is an immunotherapy drug that works by blocking a protein that inhibits the immune system, thereby enabling it to attack cancer cells. This process helps the immune system locate and destroy cancerous cells.
Previously, Nivolumab was administered intravenously over a period of 30 to 60 minutes. The new subcutaneous injection method significantly reduces treatment time to just 3 to 5 minutes.
NHS England estimates that the faster governance of Nivolumab will save approximately 1,000 hours of doctor’s time each month. The NHS currently treats around 1,200 cancer patients monthly with Nivolumab.
Professor Peter Johnson, NHS england’s national clinical director for cancer, stated that the new treatment is applicable to 15 different cancers, including lung, kidney, bladder, esophageal, skin, and neck cancers.
The expedited Nivolumab injections will free up valuable time in clinical trials, allowing for the treatment of more patients and increasing overall hospital capacity, according to the NHS.
James Richardson, a clinical pharmacist and national advisor for cancer drugs, hailed the new method as a significant advancement in cancer treatment. He noted that this faster, more effective treatment has the potential to improve the lives of thousands of patients every month.
UK’s NHS to Offer Faster Cancer Treatment with Subcutaneous nivolumab: Your questions Answered
Q: What is the National Health Service (NHS) doing to improve cancer treatment in the UK?
A: Starting next June, the NHS in the United Kingdom will introduce subcutaneous injections of Nivolumab (Opdivo) for treating 15 different types of cancer. This makes the UK the first European nation to use this method of administration.
Q: What is Nivolumab (Opdivo) and how does it work?
A: Nivolumab is an immunotherapy drug. It effectively works by blocking a protein that inhibits the immune system, allowing the immune system to attack cancer cells. This process helps the body locate and destroy cancerous cells.
Q: How is the new subcutaneous injection method different from the previous method?
A: Previously, Nivolumab was administered intravenously, which took 30 to 60 minutes. The new subcutaneous injection method substantially reduces treatment time to just 3 to 5 minutes.
Q: What are the benefits of subcutaneous Nivolumab treatment?
A: There are several benefits. Firstly, it saves a significant amount of time. The NHS estimates that the faster administration will save approximately 1,000 hours of doctor’s time each month. This allows for more consultations and appointments.Secondly, it frees up valuable time in clinical trials, allowing more patients to be treated. it increases hospital capacity.
Q: How many cancer patients in the UK will benefit from this new treatment?
A: The NHS currently treats around 1,200 cancer patients monthly with Nivolumab. All of these patients, and potentially more, will benefit from the faster subcutaneous injection method.
Q: What types of cancer can be treated with subcutaneous Nivolumab?
A: According to Professor Peter Johnson,NHS England’s national clinical director for cancer,the new treatment is applicable to 15 different cancers,including:
Lung cancer
Kidney cancer
Bladder cancer
Esophageal cancer
skin cancer
Neck cancer
Q: How does this new treatment impact healthcare efficiency?
A: The shorter treatment time means that healthcare professionals will have more time to see other patients and focus on other critical tasks. James richardson, a clinical pharmacist and national advisor for cancer drugs, highlighted that this faster treatment has the potential to improve the lives of thousands of patients every month.
Q: Can you summarize the key differences between the old and new Nivolumab administration methods?
A: Certainly.Here is a table summarizing the main differences:
| Feature | Intravenous (Previous Method) | Subcutaneous (New Method) |
|---|---|---|
| Administration Time | 30 to 60 minutes | 3 to 5 minutes |
| Benefits | Standard treatment | faster; Saves doctor’s time; Increased hospital capacity |